Research Topics
| G M TozerSummaryAffiliation: University of Sheffield Country: UK Publications
| Collaborators
|
Detail Information
Publications
Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expressionGabi U Dachs
Angiogenesis Research Group, Department of Pathology, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
BMC Cancer 6:280. 2006..Gene regulation under tumour conditions is governed by hypoxia inducible factor 1 (HIF-1), controlling angiogenic and metastatic pathways...- Direct visualization of electroporation-assisted in vivo gene delivery to tumors using intravital microscopy - spatial and time dependent distributionMaja Cemazar
Department of Experimental Oncology, Institute of Oncology, Zaloska 2, SI 1000 Ljubljana, Slovenia
BMC Cancer 4:81. 2004..Intravital microscopy of tumors growing in dorsal skin fold window chambers is a useful method for monitoring gene transfection, since it allows non-invasive dynamic monitoring of gene expression in tumors in a live animal... - Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant dosesGillian M Tozer
Cancer Research UK Tumour Microcirculation Group, Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom
Clin Cancer Res 15:3781-90. 2009..The therapeutic potential of combining the prototype tumor vascular-disrupting agent combretastatin A-4 3-O-phosphate (CA-4-P) with systemic nitric oxide synthase (NOS) inhibition was investigated preclinically... - Disrupting tumour blood vesselsGillian M Tozer
Academic Unit of Surgical Oncology, Division of Clinical Sciences, University of Sheffield, Floor K, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK
Nat Rev Cancer 5:423-35. 2005.... - Tumour vascular disrupting agents: combating treatment resistanceG M Tozer
University of Sheffield, Academic Unit of Surgical Oncology, K Floor, School of Medicine and Biomedical Sciences, Beech Hill Road, Sheffield S10 2RX, UK
Br J Radiol 81:S12-20. 2008..In summary, VDAs provide a novel approach to cancer treatment, which should effectively complement standard treatments, if treatment resistance is addressed by judicious combination treatment strategies... - Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumorsGillian M Tozer
Cancer Research UK Tumour Microcirculation Group, Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom
Cancer Res 68:2301-11. 2008..Results imply differences in signaling pathways between VEGF isoforms and suggest that VEGF isoforms might be useful in vascular-disrupting cancer therapy to predict tumor susceptibility to VDAs... - Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologiesChryso Kanthou
Cancer Research UK Tumour Microcirculation Group, Section of Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
Int J Exp Pathol 90:284-94. 2009..The focus is now to understand mechanisms of susceptibility and resistance to identify novel molecular targets and develop strategies that are more effective... - Tumour targeting by microtubule-depolymerizing vascular disrupting agentsChryso Kanthou
University of Sheffield, Cancer Research UK, Tumour Microcirculation Group, School of Medicine and Biomedical Sciences, Beech Hill Road, Sheffi eld, S10 2RX, UK eld ac uk
Expert Opin Ther Targets 11:1443-57. 2007..This information is essential in order to identify new targets within the tumour vasculature and to improve present therapies... - Measuring the velocity of fluorescently labelled red blood cells with a keyhole tracking algorithmC C Reyes-Aldasoro
Cancer Research UK Tumour Microcirculation Group, Academic Unit of Surgical Oncology, The University of Sheffield, K Floor, School of Medicine and Biomedical Sciences, Sheffield, UK
J Microsc 229:162-73. 2008.... - Estimation of apparent tumor vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivoConstantino Carlos Reyes-Aldasoro
Academic Unit of Surgical Oncology, The University of Sheffield, Sheffield, UK
Microcirculation 15:65-79. 2008.... - Quantitative estimation of tissue blood flow rateGillian M Tozer
Academic Unit of Surgical Oncology, University of Sheffield, School of Medicine and Biomedical Sciences, Sheffield, UK
Methods Mol Biol 467:271-86. 2009..The experimental procedures and analytical methods for both techniques are given, as well as guidelines for choosing the most appropriate method... - Application of intravital microscopy in studies of tumor microcirculationSarah Jane Lunt
University of Sheffield, School of Medicine, Department of Oncology, Sheffield, United Kingdom
J Biomed Opt 15:011113. 2010..g., confocal microscopy, multiphoton microscopy, hyperspectral imaging, and optical coherence tomography) with examples of their application to studies of tumor angiogenesis... - Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRIRoss J Maxwell
Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, UK
NMR Biomed 15:89-98. 2002..These results suggest that K(trans) values for Gd-DTPA uptake into tumours could be a useful non-invasive indicator of blood flow changes induced by anti-vascular agents such as combretastatin... - The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cellsChryso Kanthou
Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, PO Box 100, Northwood, Middlesex HA6 2JR, UK
Blood 99:2060-9. 2002.... - The biology of the combretastatins as tumour vascular targeting agentsGillian M Tozer
Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK
Int J Exp Pathol 83:21-38. 2002..This paper reviews the current understanding of the mechanism of action of the combretastatins and their therapeutic potential... - The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant dosesVivien E Prise
Tumor Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middx HA6 2JR, UK
Int J Oncol 21:717-26. 2002..It is currently being used to aid interpretation of pharmacodynamic data obtained from phase I/II clinical trials of CA-4-P and is relevant for future drug development in this area... - Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour modelsSally A Hill
Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
Int J Cancer 102:70-4. 2002..It did not do so in the spontaneous T138 tumour model. These studies indicate that the potential anti-tumour activity of CA4P when used as a single agent in clinical trials may be enhanced when used in multiple dose schedules... - Enhancement of vascular targeting by inhibitors of nitric oxide synthasePeter D Davis
Angiogene Pharmaceuticals Ltd, England, Oxford, UK
Int J Radiat Oncol Biol Phys 54:1532-6. 2002..This study investigates the enhancement of the vascular targeting activity of the tubulin-binding agent combretastatin A4 phosphate (CA4P) by various inhibitors of nitric oxide synthases... - ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculaturePeter D Davis
Angiogene Pharmaceuticals Ltd, Oxford Science Park, Oxford, United Kingdom
Cancer Res 62:7247-53. 2002..These findings show that ZD6126 is a promising antivascular agent for the treatment of solid tumors... - Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-downKatharine J Lankester
Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middx, UK
Int J Oncol 30:453-60. 2007..These results demonstrate that moderate tumor blood flow reduction following antibody administration is sufficient to improve tumor antibody retention. This is encouraging for the combination of CA-4-P and 131I-A5B7 in clinical trials... - Therapeutic targeting of the tumor vasculatureGillian M Tozer
Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital Middlesex, United Kingdom
Semin Radiat Oncol 14:222-32. 2004.... - Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imagingSusan M Galbraith
Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
J Clin Oncol 21:2831-42. 2003.... - From bench to bedside for gene-directed enzyme prodrug therapy of cancerGabi U Dachs
Angiogenesis Research Group, Department of Pathology, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
Anticancer Drugs 16:349-59. 2005.... - The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitroAndrew C Brooks
Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middx HA6 2JR, U K
Anticancer Res 23:3199-206. 2003..In vivo, CA-4-P causes rapid shutdown of tumour blood flow (within minutes) and a significant neutrophil infiltration at later times... - Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopyGillian M Tozer
Tumour Microcirculation Group, Gray Cancer Institute, P O Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK
Adv Drug Deliv Rev 57:135-52. 2005..Here, we review the current status of this work and provide some examples of its use for studying the dynamics of tumour angiogenesis and vascular function... - Radiation effects on the cytoskeleton of endothelial cells and endothelial monolayer permeabilityDorota Gabrys
Department of Radiation Oncology, Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
Int J Radiat Oncol Biol Phys 69:1553-62. 2007..To investigate the effects of radiation on the endothelial cytoskeleton and endothelial monolayer permeability and to evaluate associated signaling pathways, which could reveal potential mechanisms of known vascular effects of radiation... - Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes, and integrin-targeted vectorMaja Cemazar
Tumor Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, Northwood HA6 2JR, UK
Cancer Gene Ther 9:399-406. 2002..In conclusion, our results demonstrate that some nonviral methods of gene delivery are feasible and efficient in transfecting solid tumors. Therefore, this makes nonviral methods attractive for further development... - Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopyBeatrice M Seddon
Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom
Clin Cancer Res 8:2323-35. 2002..These findings support the use of SR 4554 as a noninvasive hypoxia marker... - Effects of tin-protoporphyrin IX on blood flow in a rat tumor modelAmel F Khelifi
Tumor Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, United Kingdom
Exp Biol Med (Maywood) 228:481-5. 2003..The results also highlight the potential usefulness of CuPP as a tumor blood flow modifier... - Targeting cancer with gene therapy using hypoxia as a stimulusGabi U Dachs
Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, UK
Methods Mol Med 90:371-87. 2004